March 31, 2020

Citation Growth Corp. to Proceed with Virtual AGM Due to COVID-19 Restrictions

CALGARY, LAS VEGAS AND DESERT HOT SPRINGS – March 31, 2020 – Citation Growth Corp. (CSE:CGRO) (OTCQX:CGOTF) (“Citation” or the “Company”), a licensed multi-state cannabis cultivator, producer and retailer, has confirmed it will go ahead with the previously announced Annual General Meeting (“AGM”) on April 23rd at 1:30 p.m. MST; however, due to persisting issues as a result of the COVID-19 pandemic, the AGM will be conducted as a live web broadcast to shareholders rather than being held in person.

“We believe that it’s important to proceed with the AGM as planned,” confirmed CEO Erik Anderson, “but due to the unprecedented effect of COVID-19, we will be forced to host the AGM via video webcast rather than in person. We feel this is the safest and most corporately responsible decision to make at this time and we’re excited to share our progress with our shareholders.”

Citation’s Voting Instruction Form (“VIF”) has been mailed out by Computershare for shareholders to vote by mail, phone or by Internet on or before 1:30 p.m. Mountain Time on Tuesday, April 21, 2020. As part of the webcast, arrangements are being made to allow for a Question and Answer period during the virtual AGM.

In related news, Citation has confirmed the appointment of Shane Dungey to its Board of Directors and is excited by the new relationships he brings from the capital markets space. Mr. Dungey was announced to Citation Board on March 12, 2020 and will be present to take questions at the AGM.

Citation also announces it has completed the first tranche of a non-brokered private placement (the “Private Placement”) of 2,783,793 unites at $0.15 per unit for gross proceeds of $417,569. Each unit consists of one common share and one share purchase warrant. Each warrant is exercisable into one common share at an exercise price of $0.22 per share for a period of eighteen months expiring September 30, 2021. The warrants are subject to an accelerated expiry date if the trading price of the Company’s common shares closes at or above $0.50 per share for a period of ten consecutive trading days. The proceeds from the Private Placement will be used for general working capital purposes. All securities issued under the Private Placement are subject to a four month hold period expiring July 31, 2020. The Company will continue to raise additional capital for specific growth projects in the second and final tranche of this financing.

Management has also released an asset-backed debt financing to the market, which will raise growth capital for their Apex facility in North Las Vegas using the existing land and buildings as security. Citation plans to upgrade the grow lights in each flower room and also expand their extraction lab to run 24/7 under two cross-over shifts daily and seek out toll processing arrangements with other local cannabis cultivators in the state.

“This initiative is our largest short-term opportunity to grow revenues substantially,” commented Anderson. “The Diamante Extraction Lab is world class and we look forward to realizing its full potential as we process our own cannabis biomass and also work with other local cultivators to bring high-end 2.0 products such as vape pens, concentrates and extracts to the Nevada market.”

In light of COVID-19, Citation is pleased to report that no interruptions to its operations in Nevada and California have occurred. Sales have been strong at both the wholesale and retail levels due to increased demand in medical and recreational cannabis products. Citation’s proprietary technology and organic growing platform for medical cannabis increases the beneficial medical ingredients in the cannabis plant and removes any secondary negative aspects of man-made chemical compounds, herbicides, fungicides and pesticides, which have been clearly shown as a source of disease-causing DNA corruption.

“The vast amount research indicates that cannabis is one of the safest consumable natural medicative herbs known to mankind,” said Dr. Josef Tyls. “The incredible fit between elements of the cannabis plant and the human endocannabinoid system allows for maximum benefit for healing and minimizes adverse secondary reactions and/or negative by-products which would impede the healing processes.”

Citation’s organic methodology encompasses a recycling design that allows for water recapture, soil remediation, thermal remediation and minimal venting where undesirable waste products and smells are mitigated. The closed loop environmental processes allow for the maximum benefit to the crops while minimizing loads upon nature, while producing the highest quality medical cannabis.

Over the coming months, Citation management plans to share more information about the organic methodologies and technologies deployed by its scientists and growers.

About Citation Growth Corp.

Citation Growth Corp. (CSE:CGRO) (OTCQX:CGOTF) is a publicly traded company that has been investing in the development of the medical and recreational cannabis space since 2014. Citation has expanded its operating portfolio over time to include cultivation, production and retail offerings in key North American legal jurisdictions such as Nevada, California, Washington and British Columbia. For more information, please visit

For Further Information:

Erik Anderson, President and CEO
1-877-438-5448 Ext 713

Neither the CSE nor its Regulation Services Provider, nor the OTCQX® has approved nor disapproved the contents of this press release. Neither the CSE, nor the OTCQX® accepts responsibility for the adequacy or accuracy of this release.

Cannabis Industry Involvement:

The Company owns marijuana licenses in California and Nevada. Marijuana is legal in each state; however, marijuana remains illegal under United States federal law and the approach to enforcement of U.S. federal law against marijuana is subject to change. Shareholders and investors need to be aware that federal enforcement actions could adversely affect their investments and that the Company’s ability to support continuing U.S.-based operations and its access private and public capital could be materially adversely affected.

The Company’s business is conducted in a manner consistent with state law and is in compliance with applicable state licensing requirements in the U.S. The Company has internal compliance procedures in place and has compliance focused attorneys engaged in jurisdictions to monitor changes in laws for compliance with U.S. federal and state law on an ongoing basis. These law firms inform any necessary changes to our policies and procedures for compliance in Canada and the U.S.

Unlike in Canada which has Federal legislation uniformly governing the cultivation, distribution, sale and possession of cannabis under the Cannabis Act (Canada), readers are cautioned that in the U.S., cannabis is largely regulated at the state level. Notwithstanding the permissive regulatory environment of medical cannabis at some of the state level, cannabis continues to be categorized as a controlled substance under the Controlled Substances Act in the U.S. and as such, cannabis-related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. Strict compliance with state laws with respect to cannabis will neither absolve the Company of liability under the U.S. federal law, nor will it provide a defense to any U.S. federal proceeding, which may be brought against the Company. Any such proceedings brought against the Company may materially adversely affect its operations and financial performance in the U.S. market.

Forward-Looking Statements:

This news release contains forward-looking statements or information that relate to our current expectations and views of future events. These statements relate to future events or future performance. Statements which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, outlook, expectations or intentions regarding the future including words or phrases such as “anticipate”, “objective”, “may”, “will”, “might”, “should”, “could”, “can”, “intend”, “expect”, “believe”, “estimate”, “predict”, “potential”, “plan”, “is designed to”, “project”, “continue”, or similar expressions suggest future outcomes or the negative thereof or similar variations. Forward-looking statements may also include, among other things, statements about the future business strategy; expectations of obtaining licenses and permits; expectations regarding expenses, sales and operations; future customer concentration; anticipated cash needs and estimates regarding capital requirements and the need for additional financing; total processing capacity; the ability to anticipate the future needs of customers; plans for future products and enhancements of existing products; future growth strategy and growth rate; future intellectual property; changes in laws and regulations; regulatory approvals and other matters; and anticipated trends and challenges in the markets in which the Company may operate.

Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, including the demand for our products; anticipated costs and ability to achieve goals; the Company’s ability to complete any contemplated transactions; historical prices of cannabis; and that there will be no regulation or law that will prevent the Company from operating its businesses; the state of the economy in general and capital markets in particular; present and future business strategies; the environment in which the Company will operate in the future; the estimated size of the cannabis market; and other factors, many of which are beyond the control of the Company. While such estimates and assumptions are considered reasonable by the management of the Company, they are inherently subject to significant business, economic, competitive and regulatory uncertainties and risks. Although the Company believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. Given these risks, uncertainties and assumptions, the reader should not place undue reliance on these forward-looking statements.

Forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: management estimated future capital expenditure costs, revenue, and timeframes for operations; business, economic and capital market conditions; the ability to manage the Company’s operating expenses, which may adversely affect the Company’s financial condition; the Company’s ability to remain competitive; regulatory uncertainties; market conditions and the demand and pricing for our products; exchange rate fluctuations; security threats; the Company’s relationships with its customers, distributors and business partners; the Company’s ability to attract, retain and motivate qualified personnel; industry competition; the impact of technology changes on the Company’s products and industry; the Company’s ability to successfully maintain and enforce its intellectual property rights and defend third-party claims of infringement of their intellectual property rights; the impact of litigation that could materially and adversely affect our business; the Company’s ability to manage its working capital; and the Company’s dependence on key personnel. The Company is not a positive cash flow company and it may not actually achieve its plans, projections, or expectations (the Company has a history of losses).

The securities of the Company are considered highly speculative due to the nature of the Company’s businesses.

Important factors that could cause actual results to differ materially from the Company’s expectations include, consumer sentiment towards the Company’s products and cannabis generally; risks related to the Company’s ability to maintain its licenses issued by governments in good standing; uncertainty with respect to the Company’s ability to grow, store and sell cannabis; risks related to the costs required to meet the obligations related to regulatory compliance; risks related to the extensive control and regulations inherent in the industry in which the Company operates; risks related to governmental regulations, including those relating to taxes and other levies; risks related an early stage business and a business involving an agricultural product and a regulated consumer product; risks related to building brand awareness in a new industry and market; risks relating to restrictions on sales and marketing activities imposed by governments; risks inherent in the agricultural business; risks relating to energy costs; risks relating to product liability claims, regulatory action and litigation; risks relating to recall or return of products; and risks relating to insurance coverage; global economic climate; equipment and building failures; increase in operating costs; decrease in the price of cannabis; security threats; government regulations; loss of key employees and consultants; additional funding requirements; volatility in the securities of the Company; changes in laws; technology failures; failure to obtain permits and licenses; anticipated and unanticipated costs; competition; risks associated with the substantial obligations of being a public company; and failure of counterparties to perform their contractual obligations. This list is not exhaustive of the factors that may affect the forward-looking statements. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in the forward-looking statements.

Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither the Company nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this news release. Neither the Company nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to the reader or any person resulting from the use of the information in this news release by the reader or its representatives or for omissions from the information in this news release.

March 31, 2020

« Back to News Feed